Somewhat Positive Press Coverage Somewhat Unlikely to Affect Catalent (CTLT) Stock Price

News coverage about Catalent (NYSE:CTLT) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.6880960038358 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Catalent opened at $40.22 on Monday, reports. The company has a debt-to-equity ratio of 2.53, a quick ratio of 1.78 and a current ratio of 2.18. The stock has a market cap of $5.36 billion, a price-to-earnings ratio of 29.79, a price-to-earnings-growth ratio of 2.14 and a beta of 1.53. Catalent has a 1-year low of $33.35 and a 1-year high of $47.87.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, May 1st. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.06. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The company’s quarterly revenue was up 17.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.38 earnings per share. analysts predict that Catalent will post 1.55 earnings per share for the current year.

Several research analysts have recently issued reports on CTLT shares. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, March 9th. KeyCorp upgraded Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price target on the stock in a research report on Wednesday, March 28th. Goldman Sachs initiated coverage on Catalent in a report on Wednesday, January 24th. They set a “buy” rating and a $50.00 target price on the stock. Bank of America lifted their target price on Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, February 6th. Finally, Raymond James upgraded Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Wednesday, March 21st. They noted that the move was a valuation call. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $45.67.

In other news, SVP William Downie sold 9,082 shares of the business’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the sale, the senior vice president now directly owns 46,986 shares in the company, valued at $1,964,014.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.70% of the company’s stock.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.

Leave a Reply